Advertisement
International
Subscribe to International

The Lead

Asia Pacific: World’s Epicenter for Hepatitis

July 29, 2014 9:06 am | Videos | Comments

With some 100 million people infected with forms of hepatitis, China is the world’s epicenter for the illness.                        

European Commission Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism

July 29, 2014 8:38 am | News | Comments

Bristol-Myers Squibb and Pfizer announced that the European Commission has approved Eliquis for...

FDA Inspects Impax's Taiwan Facility – Finds Ten Issues

July 29, 2014 8:11 am | News | Comments

Impax Laboratories announced that the FDA performed a general GMP  inspection and a Pre-...

China to Put Glaxo Investigators On Trial

July 29, 2014 5:30 am | by The Associated Press | News | Comments

A Shanghai court says American and British investigators who worked for drug maker...

View Sample

FREE Email Newsletter

PaxVax Acquires FDA-Approved Typhoid Vaccine Vivotif

July 28, 2014 9:19 am | News | Comments

PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG, as well as its manufacturing facility in Thörishaus, near Bern, Switzerland.

Obama Wants Limits on US Company Mergers Abroad

July 25, 2014 8:32 am | News | Comments

Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers.      

Allergan's OZURDEX® Receives European Positive Opinion for the Treatment of Diabetic Macular Edema

July 25, 2014 8:03 am | News | Comments

Allergan announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX ® (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema.

Advertisement

China Lifts Quarantine After Man Dies of Plague

July 24, 2014 8:25 am | News | Comments

A nine-day quarantine imposed on parts of a northern Chinese city where a man died of bubonic plague has been lifted, China's official news agency reported Thursday.              

GSK Asks European Regulator to OK Malaria Shot

July 24, 2014 8:18 am | News | Comments

The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization.

EU Regulator: Morning-After Pill OK for All Women

July 24, 2014 8:11 am | News | Comments

The European Medicines Agency says a commonly used morning-after pill is suitable for use by heavier women after reviewing the evidence, sparked by a French pharmaceutical company's declaration last year that the drugs didn't work in women weighing more than 176 pounds.

West Dedicates Pharmaceutical Manufacturing Plant in India

July 16, 2014 8:41 am | News | Comments

In June 2012, West signed a 99-year lease on 72,800 square meters (approximately 783,600 square feet) of land in Sri City. Sri City offers the advantages of a metropolitan location and was selected primarily on the suitability of land, availability of utilities, labor suitability, logistics and quality of life.

China Indicts US, British Nationals Involved In GSK Investigation

July 13, 2014 11:26 pm | by The Associated Press | News | Comments

Chinese authorities formally indicted two corporate investigators, an American and Briton, for allegedly illegally obtaining and selling private information, state media reported Monday. Prosecutors in Shanghai filed charges against British investigator Peter Humphrey and his wife Yingzeng Yu, a U.S. citizen, at the city's No. 1 Intermediate People's Court, the official Xinhua News Agency said.

Advertisement

ScinoPharm President and CEO to Retire

July 11, 2014 8:04 am | News | Comments

ScinoPharm announced that after 17 years of dedicated service, its co-founder and President & CEO Dr. Jo Shen is retiring at the end of July 2014 and will be succeeded by Dr. Yung-Fa (Fred) Chen, currently Sr. Vice President of R&D and Chief Technology Officer, effective August 1, 2014.

Salix Pharmaceuticals to Combine with Cosmo Technologies to Form Salix Pharmaceuticals, plc

July 9, 2014 8:57 am | News | Comments

Salix Pharmaceuticals, Ltd. and Cosmo Pharmaceuticals S.p.A. announced a definitive merger agreement under which Salix will combine with Cosmo Technologies Limited (“Cosmo Tech”), a subsidiary of Cosmo. Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Irish domiciled Cosmo Tech.

$580M EU Antitrust Fine for Drug Makers

July 9, 2014 8:14 am | News | Comments

The European Union's antitrust body is imposing a fine of 428 million euros ($580 million) on France's pharmaceutical company Servier and five producers of generic medicines for distorting competition.        

Incyte Get $25M Milestone Payment from Novartis after Jakavi® Approval in Japan

July 8, 2014 9:01 am | News | Comments

Incyte Corporation announced today that it has earned a $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis.      

Hospira Completes Acquisition of Orchid's API Manufacturing and R&D Facility

July 7, 2014 8:31 am | News | Comments

Hospira has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., an Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.

Advertisement

Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® and Sunvepra® Dual Regimen

July 7, 2014 8:19 am | News | Comments

Bristol-Myers Squibb Company has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor ( in vitro ), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options.

US Officials Barred from American's Trial in China

July 4, 2014 5:25 am | by The Associated Press | News | Comments

A U.S. Embassy spokesman says diplomats are barred from the trial in Shanghai of an American investigator for GlaxoSmithKline and her British husband who are charged with improperly selling personal information. Spokesman Nolan Barkhouse said Friday that the U.S. government is concerned about lack of access to the trial of Yu Yingzeng and husband Peter Humphrey in August.

Pakistan Refugee Crisis Creates Polio Challenge

June 30, 2014 8:50 am | by REBECCA SANTANA, Associated Press; IJAZ MUHAMMED, Associated Press | News | Comments

The rugged Pakistani region of North Waziristan emerged as a hotbed of polio infections after Taliban militants in the isolated area banned immunizations. Now the Pakistani government's offensive against the militants has sent a half-million refugees fleeing the territory, creating both perfect conditions for the disease to spread and a golden opportunity to immunize many thousands of people.

Can Shareholders Stop a Company From Going Global?

June 27, 2014 8:53 am | Videos | Comments

A group of shareholders, led by Yujiro Hara, opposes the hiring of foreign executives at Takeda Pharmaceutical, the biggest drug company in Japan, calling it a “hijacking by foreign capital.”          

EYLEA Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the EU

June 27, 2014 8:33 am | News | Comments

Regeneron Pharmaceuticals today announced that EYLEA (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to diabetic macular edema (DME).

Vertex Receives European CHMP Positive Opinion for KALYDECO in Eight Non-G551D Gating Mutations

June 27, 2014 8:24 am | News | Comments

Vertex Pharmaceutical today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of KALYDECO™ (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

June 27, 2014 8:20 am | News | Comments

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes.   

More Countries Adding Graphic Warnings to Cigarettes

June 27, 2014 8:08 am | by MARGIE MASON, Associated Press | News | Comments

Indonesia became the newest country to mandate graphic photo warnings on cigarette packs on Tuesday, joining more than 40 other nations or territories that have adopted similar regulations in recent years.        

Europe Euthanasia Rulings Spark Debate

June 25, 2014 8:35 am | by LORI HINNANT, Associated Press | News | Comments

A French doctor was acquitted Wednesday of poisoning charges after giving lethal injections to seven terminally ill patients, and Britain's Supreme Court said an assisted-suicide ban is incompatible with human rights, fueling the arguments of those who say the duty of doctors is to end the suffering of those beyond treatment.

Abbott to Acquire Russia's Veropharm

June 24, 2014 8:23 am | News | Comments

Abbott has announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer. Under the terms of the agreement, Abbott will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between 13.6 billion rubles and 17 billion rubles (or a range of approximately $395 million to $495 million U.S. dollars)

Shire Rejects Offer from AbbVie

June 20, 2014 7:33 am | by The Associated Press | News | Comments

The Dublin-based drugmaker Shire said Friday it has rejected an unsolicited 27 billion-pound ($46.2 billion) offer from AbbVie Inc., arguing that it fundamentally undervalues the company and its prospects. The company said in a statement Friday that U.S.-based AbbVie's proposal was for 20.44 pounds ($34.78) and 0.7988 shares per Shire share.

ViiV Healthcare to Collaborate with Janssen to Develop Single-Tablet HIV-1 Treatment

June 13, 2014 8:51 am | News | Comments

ViiV Healthcare has entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialization of a single-tablet combining dolutegravir (Tivicay) and Janssen's non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant).

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading